BBS-Bioactive Bone Substitutes Plc, Company Release, March 17th, 2022 at 3.30 pm
BBS-Bioactive Bone Substitutes Plc: Decisions of the Extraordinary General Meeting 2022
BBS-Bioactive Bone Substitutes Plc’s Extraordinary General Meeting (EGM) was held today, on Thursday 17th March 2022 from 2:00 pm in Oulu.
The Extraordinary General Meeting decided to authorize the Board of Directors to decide in one or more instalments on share issues and on the issuance of option rights and other special rights entitling to shares referred to in Chapter 10, Section 1 of the Finnish Limited Liability Companies Act as follows:
The minutes of the EGM will be available on the Company’s website www.bbsartebone.fi no later than March 31st 2022.
For more information:
Certified Advisor: Nordic Certified Adviser AB, p. +46 70 551 67 29, firstname.lastname@example.org
Nasdaq Helsinki Oy Nasdaq Stockholm AB
BBS-Bioactive Bone Substitutes Plc is the health technology company operating since 2003. Before that there was a background of seven years of product development in the University of Oulu. We have developed a new product for healing of difficult bone fractures and for solving the problems in bone healing. Our mission is to offer new generation medicinal products for the orthopedic surgery. The research and development in the field of medicine requires perseverance and courage to develop new things. We have over 20 years of expertise in this. Our operations are characterized by top expertise, innovativeness and dedicated and committed employees. The ARTEBONE ®product is ready and the application process for the CE-mark has been initiated. BBS is the company having its headquarters in Oulu. We have our own production plant located in Reisjärvi and it is approved by FIMEA. More information: www.bbs-artebone.fi